These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 1898744)

  • 21. Indices of insulin sensitivity, beta cell function and serum proinsulin levels in the polycystic ovary syndrome.
    Panidis D; Macut D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Spanos N; Petakov M; Bjekic J; Damjanovic S
    Eur J Obstet Gynecol Reprod Biol; 2006 Jul; 127(1):99-105. PubMed ID: 16460870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction.
    Hamilton-Fairley D; Kiddy D; Anyaoku V; Koistinen R; Seppälä M; Franks S
    Clin Endocrinol (Oxf); 1993 Sep; 39(3):363-7. PubMed ID: 7693380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SHBG, testosterone, androstenedione, 17-OH-Progesterone plasma levels in PCO affected women treated with a triphasic oral contraceptive.
    Negri P; Agnello G; Borghesani F; Tomain L; Minisci N; D'Errico G; Cavallini AR
    Acta Eur Fertil; 1987; 18(6):375-80. PubMed ID: 3454501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome.
    Moran C; Renteria JL; Moran S; Herrera J; Gonzalez S; Bermudez JA
    Fertil Steril; 2008 Dec; 90(6):2310-7. PubMed ID: 18163993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
    Mehta RV; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Dietary Approach to Stop Hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial.
    Azadi-Yazdi M; Karimi-Zarchi M; Salehi-Abargouei A; Fallahzadeh H; Nadjarzadeh A
    J Hum Nutr Diet; 2017 Jun; 30(3):275-283. PubMed ID: 28466507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity, serum steroid levels, and pulsatile gonadotropin secretion in polycystic ovarian disease.
    Laatikainen T; Tulenheimo A; Andersson B; Kärkkäinen J
    Eur J Obstet Gynecol Reprod Biol; 1983 Apr; 15(1):45-53. PubMed ID: 6224711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
    Dunaif A; Scott D; Finegood D; Quintana B; Whitcomb R
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3299-306. PubMed ID: 8784087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia.
    Rajkhowa M; Bicknell J; Jones M; Clayton RN
    Fertil Steril; 1994 Apr; 61(4):605-12. PubMed ID: 8150099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Correlation between hormonal and metabolic profiles in women with polycystic ovary syndrome].
    Esposito V; Federico P; Lo Iudice G; Rispoli C; Sabatino P; D'Alessandro B
    Minerva Endocrinol; 1992; 17(1):21-9. PubMed ID: 1495451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.
    Kiddy DS; Hamilton-Fairley D; Bush A; Short F; Anyaoku V; Reed MJ; Franks S
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):105-11. PubMed ID: 1559293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome.
    Dunaif A; Graf M
    J Clin Invest; 1989 Jan; 83(1):23-9. PubMed ID: 2642919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS.
    Van Dam EW; Roelfsema F; Veldhuis JD; Helmerhorst FM; Frölich M; Meinders AE; Krans HM; Pijl H
    Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E865-72. PubMed ID: 11882506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leptin levels in women with polycystic ovary syndrome before and after treatment with diazoxide.
    Krassas GE; Kaltsas TT; Pontikides N; Jacobs H; Blum W; Messinis I
    Eur J Endocrinol; 1998 Aug; 139(2):184-9. PubMed ID: 9724074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome.
    Sir-Petermann T; Ladrón de Guevara A; Codner E; Preisler J; Crisosto N; Echiburú B; Maliqueo M; Sánchez F; Perez-Bravo F; Cassorla F
    Reprod Sci; 2012 Apr; 19(4):383-90. PubMed ID: 22344736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obese patients with polycystic ovary syndrome: evidence that metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids.
    Eagleson CA; Bellows AB; Hu K; Gingrich MB; Marshall JC
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5158-62. PubMed ID: 14602743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.